Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial.

被引：0
|
作者：
Ahn, Myung-Ju
Kim, HyeRyun
Yang, James Chih-Hsin
Han, Ji-Youn
Lee, Jong Seok
Hochmair, Maximilian J.
Li, Jacky Yu-Chung
Chang, Gee-Chen
Lee, Ki Hyeong
Gridelli, Cesare
Campelo, Rosario Garcia
Delmonte, Angelo
Kim, Dong-Wan
Kerstein, David
Ni, Quanhong
Zhang, Pingkuan
Popat, Sanjay
Camidge, D. Ross
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[2] Yonsei Univ, Severance Hosp, Seoul, South Korea
[3] Natl Taiwan Univ, Taipei, Taiwan
[4] Natl Canc Ctr, Ctr Lung Canc, Goyang, Gyeonggi Do, South Korea
[5] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
[6] Dept Resp & Crit Care Med, Vienna, Austria
[7] Ludwig Boltzmann Inst COPD & Resp Epidemiol, Vienna, Austria
[8] Hong Kong United Oncol Ctr, Kowloon, Hong Kong, Peoples R China
[9] Taichung Vet Gen Hosp, Div Chest Med, Dept Internal Med, Taichung, Taiwan
[10] Natl Yang Ming Univ, Fac Med, Sch Med, Taipei, Taiwan
[11] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea
[12] AOSG Moscati, Avellino, Italy
[13] Complejo Hosp Univ A Coruna, Coruna, Spain
[14] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy
[15] Seoul Natl Univ Hosp, Seoul, South Korea
[16] Millennium Pharmaceut Inc, Cambridge, MA USA
[17] Royal Marsden Hosp, London, England
[18] Univ Colorado, Ctr Canc, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9026
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Brigatinib (BRG) vs crizotinib (CRZ) in Asian vs non-Asian patients (pts): Update from ALTA-1L
    Ahn, M-J.
    Kim, H. R.
    Yang, J. C-H.
    Han, J-Y.
    Li, J. Y-C.
    Hochmair, M. J.
    Chang, G-C.
    Delmonte, A.
    Lee, K. H.
    Garcia Campelo, M. R.
    Gridelli, C.
    Spira, A.
    Califano, R.
    Griesinger, F.
    Ghosh, S.
    Felip, E.
    Kim, D-W.
    Zhang, P.
    Popat, S.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2020, 31 : S843 - S844
  • [2] Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial
    Califano, R.
    Hochmair, M. J.
    Gridelli, C.
    Delmonte, A.
    Garcia Campelo, M. R.
    Bearz, A.
    Griesinger, F.
    Morabito, A.
    Felip, E.
    Ghosh, S.
    Tiseo, M.
    Haney, J.
    Kerstein, D.
    Popat, S.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2019, 30 : 41 - 41
  • [3] Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK plus NSCLC in the phase II ALTA trial
    Lee, D. H.
    Kim, D-W.
    Camidge, D. R.
    Langer, C. J.
    Huber, R. M.
    Tiseo, M.
    West, H. L.
    Groen, H. J. M.
    Reckamp, K. L.
    Hochmair, M. J.
    Leighl, N. B.
    Hansen, K. H.
    Gettinger, S. N.
    Paz-Ares, L.
    Kim, E. S.
    Smit, E. F.
    Kim, S-W.
    Ni, Q.
    Zhang, P.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2019, 30 : 634 - +
  • [4] Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial
    Popat, S.
    Kim, H. R.
    Ahn, M-J.
    Yang, J. C-H.
    Han, J-Y.
    Hochmair, M. J.
    Lee, K. H.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D-W.
    Griesinger, F.
    Felip, E.
    Califano, R.
    Spira, A. I.
    Gettinger, S.
    Tiseo, M.
    Haney, J.
    Kerstein, D.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2018, 29 : 746 - 746
  • [5] Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ): Updated results from the ALTA-1L trial
    Popat, S.
    Kim, H. R.
    Ahn, M-J.
    Yang, J. C-H.
    Han, J-Y.
    Hochmair, M. J.
    Lee, K. H.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D-W.
    Griesinger, F.
    Felip, E.
    Califano, R.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Ni, Q.
    Zhang, P.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2020, 31 : S840 - S841
  • [6] Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK plus NSCLC from ALTA-1L
    Yang, James C. H.
    Kim, Hye R.
    Ahn, Myung-Ju
    Han, Ji-Youn
    Hochmair, Maximilian J.
    Lee, Ki H.
    Delmonte, Angelo
    Garcia Campelo, Maria R.
    Kim, Dong-Wan
    Felip, Enriqueta
    Califano, Raffaele
    Spira, Alexander
    Gettinger, Scott
    Tiseo, Marcello
    Haney, Jeff
    Kerstein, David
    Popat, Sanjay
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [7] Brigatinib vs crizotinib in the phase 3 ALTA-1L trial: Updated results
    Griesinger, F.
    Kim, H. R.
    Ahn, M. -J.
    Yang, J. C.
    Han, J. -Y.
    Hochmair, M.
    Lee, K. H.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D. -W.
    Felip, E.
    Califano, R.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Lin, H.
    Liu, Y.
    Zhang, P.
    Popat, S.
    Camidge, D. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 142 - 142
  • [8] Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI-naive ALK plus NSCLC: Final results from ALTA-1L
    Popat, S.
    Kim, H. R.
    Ahn, M-J.
    Yang, J. C.
    Han, J-Y.
    Hochmair, M. J.
    Lee, K. H.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D-W.
    Griesinger, F.
    Felip, E.
    Califano, R.
    Spira, A.
    Gettinger, S. N.
    Tiseo, M.
    Lin, H. M.
    Liu, Y.
    Vranceanu, F.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S954 - S955
  • [9] Quality-adjusted survival with brigatinib (BRG) versus crizotinib (CRZ) in ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC): Results from the ALTA-1L trial
    Campelo, M. R. Garcia
    Wan, Y.
    Lin, M.
    Chen, T.
    Shen, J.
    Zhang, P.
    Humphries, M. J.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1077 - S1078
  • [10] Updated Results from the Phase 3 ALTA-1L Trial of Brigatinib (BRG) vs. Crizotinib (CRZ) in ALK Inhibitor-Naive Advanced ALK plus NSCLC
    Griesinger, Frank
    Camidge, D. Ross
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James Chih-Hsin
    Han, Ji Youn
    Hochmair, Maximilian
    Lee, Hyeong
    Delmonte, Angelo
    Garcia Compelo, Maria Rosario
    Kim, Dong-Wan
    Felip, Enriqueta
    Califano, Raffaele
    Spire, Alexander
    Gettinger, Scott N.
    Tiseo, Marcello
    Lin, Huamao M.
    Ni, Quanhong
    Zhang, Pingkuan
    Popat, Sanjay
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 232 - 232
12345